


Claims

1. The use of compounds of the formula I



5 in which

Ar is an aromatic or heteroaromatic ring system,

$\text{X}^1$  is  $\text{NR}^3\text{R}^4$ ,  $\text{OR}^3$ ,  $\text{SR}^3$ ,  $\text{COOR}^3$ ,  $\text{CONR}^3\text{R}^4$  or  $\text{COR}^5$ ,

$\text{R}^1$  is H, an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical, or  $\text{COOR}^3$ ,  $\text{CONR}^3\text{R}^4$  or  $\text{COR}^5$ ,

$\text{R}^2$  is halogen,  $\text{C(R}^6\text{)}_3$ ,  $\text{C}_2(\text{R}^6)_5$ ,  $\text{OC(R}^6\text{)}_3$  or  $\text{OC}_2(\text{R}^6)_5$ ,

$\text{R}^3$  is H or any organic radical,

$\text{R}^4$  is H or an unsubstituted or substituted alkyl, alkenyl or alkynyl radical,

$\text{R}^5$  is H, an alkyl, alkenyl, alkynyl, carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxyaryl or carboxyheteroaryl radical, where the alkyl, aryl and heteroaryl radicals may be unsubstituted or substituted,

$\text{R}^6$  is in each case independently H or halogen, in particular F, and

m is an integer from 0 to 4,

or salts of said compounds for preparing an agent for inhibition of the urokinase plasminogen activator.

2. The use of compounds as claimed in claim 1, in which Ar is a benzene ring.

3. The use of compounds as claimed in claim 2, in which the substituents  $\text{-CHX}^1\text{R}^1$  and  $\text{-NHC(NH)NH}_2$  are arranged in para position.

- $$\begin{array}{c} \text{---} \\ | \\ \text{X}^2 \end{array} \text{---} [\text{Y}]_n \text{---} \text{X}^3 \text{---} \text{R}^7 \quad (\text{II})$$


$X^2$  is  $NH$ ,  $NR^4$ ,  $O$  or  $S$ ,

$Y$  is  $C(R^8)_2$ ,

10 R<sup>7</sup> is H or an unsubstituted or substituted  
alkyl, alkenyl, alkynyl, aryl or/and  
heteroaryl radical or -SO<sub>2</sub>-R<sup>9</sup>,


R<sup>9</sup> is H or an unsubstituted or substituted alkyl, alkenyl, alkynyl, aryl or/and heteroaryl radical and

5. The use of compounds as claimed in any of claims 1 to 4, in which R<sup>3</sup> is a group of the formula IIIa, IIIb or IIIc:



in which  $R^7$  and  $R^9$  are as defined in claim 4.

- 10 7. The use as claimed in any of claims 1 to 6, :  
characterized in that  
the compounds have the formula IV:



15 Ar,  $X^1$ ,  $R^2$  and m, on each occurrence, independently  
may be identical or different and have a  
meaning as defined in claim 1.

9. The use as claimed in claim 8 for controlling  
tumors.


- 30 11. The use as claimed in any of the preceding claims  
for preparing orally, topically, rectally or  
parenterally administrable medicaments.

12. The use as claimed in any of the preceding claims in the form of tablets, coated tablets, capsules,

ories, solu  
asters.

nhibiting  
particular  
effective  
aimed in an


formula (I)



¹, R² and m

- 5

- (11)



10

in which  $Ar$ ,  $X^1$ ,  $R^1$ ,  $R^2$  and  $m$  are as defined in any of claims 1 to 7.

Add  $A_2$

add (B3)